Please login to the form below

Not currently logged in
Email:
Password:

Roche signs exclusive distribution deal

Roche has signed an exclusive distribution deal with DxS for two cancer tests designed to help assist doctors in identifying suitable patients for treatment
Roche has signed an exclusive distribution deal with DxS for two cancer tests designed to help assist doctors in identifying suitable patients for treatment.

The K-RAS test will aid in the selection of suitable colorectal cancer patients for treatment, whereas the EGFR 29 test will aid doctors in selecting lung cancer patients suitable for treatment with some inhibitor therapies.

The European Commission recently granted a conditional marketing authorisation for a potential treatment for patients with non-mutated K-RAS genes who do not respond to standard chemotherapy regimens.

Daniel O'Day, president and CEO of Roche Molecular Diagnostics said: "There is a growing demand for tests to indicate disease prognosis and identify patient groups more likely to benefit from a particular drug."

Roche has been granted exclusive worldwide distribution rights for the K-RAS test, and exclusive distribution rights inall global markets except the US, Canada, Mexico and Hong Kong for the EGFR 29 test. Both tests have CE Mark certification in Europe.

"Not only does it [the distribution agreement] enable us to meet the growing demand for these tests, but it also gives doctors and patients access to standardised test results that provide further information to enhance treatment decisions," said Dr Stephen Little, CEO of DxS.

2nd June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics